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Abstract
Linagliptin (TRADJENTA
TM) is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor. DPP-4 inhibition attenuates insulin resistance
and improves peripheral glucose utilization in humans. However, the effects of chronic DPP-4 inhibition on insulin
sensitivity are not known. The effects of long-term treatment (3–4 weeks) with 3 mg/kg/day or 30 mg/kg/day linagliptin on
insulin sensitivity and liver fat content were determined in diet-induced obese C57BL/6 mice. Chow-fed animals served as
controls. DPP-4 activity was significantly inhibited (67–89%) by linagliptin (P,0.001). Following an oral glucose tolerance
test, blood glucose concentrations (measured as area under the curve) were significantly suppressed after treatment with
3 mg/kg/day (–16.5% to –20.3%; P,0.01) or 30 mg/kg/day (–14.5% to –26.4%; P,0.05) linagliptin (both P,0.01). Liver fat
content was significantly reduced by linagliptin in a dose-dependent manner (both doses P,0.001). Diet-induced obese
mice treated for 4 weeks with 3 mg/kg/day or 30 mg/kg/day linagliptin had significantly improved glycated hemoglobin
compared with vehicle (both P,0.001). Significant dose-dependent improvements in glucose disposal rates were observed
during the steady state of the euglycemic–hyperinsulinemic clamp: 27.3 mg/kg/minute and 32.2 mg/kg/minute in the
3 mg/kg/day and 30 mg/kg/day linagliptin groups, respectively; compared with 20.9 mg/kg/minute with vehicle (P,0.001).
Hepatic glucose production was significantly suppressed during the clamp: 4.7 mg/kg/minute and 2.1 mg/kg/minute in the
3 mg/kg/day and 30 mg/kg/day linagliptin groups, respectively; compared with 12.5 mg/kg/minute with vehicle (P,0.001).
In addition, 30 mg/kg/day linagliptin treatment resulted in a significantly reduced number of macrophages infiltrating
adipose tissue (P,0.05). Linagliptin treatment also decreased liver expression of PTP1B, SOCS3, SREBP1c, SCD-1 and FAS
(P,0.05). Other tissues like muscle, heart and kidney were not significantly affected by the insulin sensitizing effect of
linagliptin. Long-term linagliptin treatment reduced liver fat content in animals with diet-induced hepatic steatosis and
insulin resistance, and may account for improved insulin sensitivity.
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Introduction
Nutrient intake stimulates the release of the incretin hormones
glucose-dependent insulinotropic polypeptide (GIP) and glucagon-
like peptide-1 (GLP-1) into the circulation [1–3]. The important
functions of both these incretins include potentiating glucose-
dependent insulin secretion from pancreatic b-cells and inhibiting
glucagon secretion, which in turn reduces hepatic gluconeogenesis
[2,4,5]. The ‘incretin effect’ is significantly reduced in patients with
type 2 diabetes mellitus (T2DM) and contributes to impaired
insulin secretion and chronic hyperglycemia [6,7]. Under normal
physiologic conditions, dipeptidyl peptidase-4 (DPP-4) rapidly
degrades GIP and GLP-1 [2,4]. Thus, the inhibition of DPP-4 is a
therapeutic option to extend the half-life of endogenous GIP and
GLP-1, and lower hyperglycemia in patients with T2DM. Several
DPP-4 inhibitors have demonstrated a favorable safety and
tolerability profile in clinical studies of patients with T2DM
[2,8]. Other beneficial effects observed in animal and in vitro
studies include inhibition of b-cell apoptosis [9] caused by
glucotoxicity and/or lipotoxicity [10], modulation of b-cell mass
and islet cell proliferation [11,12], and differentiation of pancreatic
ductal cells into insulin-producing cells [13].
Linagliptin, a xanthine-based, highly potent and long-acting
non-peptidomimetic DPP-4 inhibitor, was recently approved in
the United States for the treatment of T2DM [14,15]. In both
animal and in vitro studies, linagliptin demonstrated a greater
inhibition of DPP-4 than alogliptin, saxagliptin, sitagliptin or
vildagliptin [15]. After absorption, linagliptin binds to plasma
proteins in a concentration-dependent manner, giving the drug a
nonlinear pharmacokinetic profile [16]. Unlike other DPP-4
inhibitors that are cleared by the kidneys, linagliptin is mainly
excreted in the feces [17,18]. The high therapeutic index and
placebo-like safety profile of linagliptin support once-daily dosing
in patients with T2DM, with no requirement for dose adjustment
in patients with declining renal function [4,19].
A pilot study in 16 patients with T2DM reported improved
insulin sensitivity after 6 weeks of treatment with the DPP-4
inhibitor vildagliptin [20]. In another study, sitagliptin prevented
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38744the development of metabolic and hormonal disturbances, and
increased b-cell apoptosis and liver steatosis induced by a fructose-
rich diet in normal rats [21]. Long-term treatment with the DPP-4
inhibitor P32/98 caused sustained improvements in glucose
tolerance, insulin sensitivity, hyperinsulinemia and b-cell glucose
responsiveness in Vancouver diabetic fatty (fa/fa) Zucker rats [22]
and in glucokinase haploinsufficient diabetic mice [23]. We
therefore tested the hypothesis that long-term (3–4 weeks)
linagliptin treatment in mice with diet-induced obesity (DIO)
would improve insulin sensitivity. In addition, we investigated the
effects of linagliptin treatment on glycemic control and liver fat
content.
Methods
Experimental Animals and Study Design
Ten-week-old female C57BL/6N mice (n=57) were pur-
chased from Charles River (Boston, MA). The study design
comprised four individual studies (Table 1) in which obesity was
induced by feeding the mice a high-fat diet (60 kcal% fat;
Research Diets D12492, Open Source Diets, New Brunswick,
NJ) for 2, 3 or 4 months, depending on the study protocol.
Chow-fed mice (n=15) were used as controls for all the studies.
Therapeutic intervention with linagliptin or vehicle was initiated
after the high-fat feeding period for 3 or 4 additional weeks.
Linagliptin (3 or 30 mg/kg in 0.5% Natrosol) was administered
orally once-daily between 0800 and 0900 using a cannula;
Natrosol alone was used as vehicle control. Clamp studies and
magnetic resonance spectroscopy (MRS) studies used 15 and
nine animals per group, respectively. Fed plasma glucose
concentrations were measured once weekly before treatment.
Experiments were performed in accordance with the rules for
animal care of the local government authorities and were
approved by the animal care and use committee of Leipzig
University as well as by the animal care committee of the
Bezirksregierung Leipzig, Germany (Approval ID: TVV 27/08).
Measurement of DPP-4 Activity
Aliquots of 20 ml plasma in EDTA were diluted with 30 mlo f
DPP-4 assay buffer (100 mM Tris, 100 mM NaCl, adjusted to
pH 7.8 with HCl) and mixed with 50 ml of substrate, H-Ala-Pro-7-
amido-4-trifluoromethylcoumarin (Bachem, Bubendorf, Switzer-
land) to a final concentration of 100 mM. The reaction was
incubated at room temperature for 10 minutes and DPP-4 activity
measured as fluorescence emission at 535 nm with excitation at
405 nm using a Wallac, Victor
TM 1420 Multilabel Counter
(PerkinElmer, Waltham, MA).
Oral glucose Tolerance Tests
Oral glucose tolerance tests (OGTT) were performed after an
overnight fast for 16 hours. Animals were orally loaded with 2 g/
kg body weight glucose and tail vein blood was collected at 0
(baseline), 15, 30, 60 and 120 minutes following challenge. Blood
glucose concentration was measured with a glucometer (One-
TouchH UltraH; Lifescan, Milpitas, CA).
Euglycemic–hyperinsulinemic Clamp Studies (Study 2)
For catheter implantation, mice were anesthetized in the fed
state 4 weeks after the start of treatment with an intraperitoneal
injection of 240 mg/kg body weight Avertin
H (2,2,2 Tribromo-
ethanol, 2-methyl-2-butanol; Sigma Aldrich, Hamburg, Ger-
many).
After loss of pedal reflex was confirmed, a catheter (Micro-
RenathaneH tubing, MRE 025; Braintree Scientific Inc., Brain-
tree, MA) was inserted into the right internal jugular vein and
advanced to the superior vena cava [24]. The vein was then
ligated distally. The catheter was filled with 100 ml of NaCl/
heparin sulfate solution to prevent clotting. The end of the
catheter was tunneled to the supra scapular region. Mice were
administered intraperitoneal injections of 1 ml saline containing
15 mg/g body weight of tramadol and placed on a heating pad to
facilitate recovery.
Euglycemic–hyperinsulinemic clamps were performed on ani-
mals in the fed state 3 days after catheter implantation. After a 5-
mCi bolus injection of D-[3-
3H]glucose (Amersham Biosciences,
Little Chalfont, UK), the tracer was infused continuously
(0.05 mCi/minute) for the duration of the experiment. Baseline
parameters were determined using a 50-ml aliquot of blood
collected at the end of the 40-minute run-in period. To minimize
blood loss, red blood cells were collected by centrifugation,
resuspended in saline and re-infused. A bolus of insulin (40 mU/g;
Actrapid 40U, Novo Nordisk, Copenhagen, Denmark) solution
containing 0.1% bovine serum albumin (BSA; Sigma-Aldrich,
Hamburg, Germany) was injected followed by infusion at a fixed
rate (4 mU/g/minute). Blood glucose levels were determined
every 10 minutes (B-Glucose Analyzer; HemoCue AB, A ¨ngelholm,
Sweden). Physiological blood glucose concentrations (between 120
and 150 mg/dl) were maintained by adjusting infusion of a 20%
glucose (DeltaSelect, Rimbach, Germany) solution. Approximately
60 minutes before steady state was achieved, a bolus of 2-deoxy-D-
[1-
14C]glucose (10 mCi; Amersham Biosciences, Little Chalfont,
UK) was infused. Steady state was ascertained when glucose
measurements were constant for $30 minutes at a fixed glucose
infusion rate and was achieved within 120–150 minutes. During
the clamp experiment, 5-ml blood samples were collected after
infusion of the 2-deoxy-D-[1-
14C]glucose at 0 and 5 minutes, and
Table 1. Study design.
Study Duration of HFD (months)
Duration of linagliptin
treatment (weeks) Animals per group (n) Outcome measures
1 2 4 9 Liver fat content (MRS) OGTT
2 3 4 15 Insulin sensitivity (clamp) OGTT
3 3 3 9 Liver fat content (MRS) OGTT
4 4 4 9 Liver fat content (MRS) OGTT
Female C57BL/6N mice were fed with a HFD (60% calories from fat) or a chow diet (10% calories from fat) for either 2, 3 or 4 months. Therapeutic intervention was
initiated following the feeding period either for 3 or 4 additional weeks. Linagliptin was administered orally daily in doses of 3 mg/kg or 30 mg/kg in 0.5% Natrosol (or
Natrosol alone as vehicle control). One group of chow-fed mice (n=15) was used as comparators for all studies.
HFD, high-fat diet; MRS, magnetic resonance spectroscopy; OGTT, oral glucose tolerance test.
doi:10.1371/journal.pone.0038744.t001
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reached. Once steady state had been reached, 50-ml blood samples
were collected for the measurement of steady-state parameters. At
the end of the experiment, mice were euthanized with an AvertinH
overdose, and epigonadal adipose tissue, subcutaneous adipose
tissue, skeletal muscle, liver, brain, kidney and heart were taken
and stored for biochemical/molecular analyses. Plasma [3-
3H]glu-
cose and deoxy-[1-
14C]glucose radioactivity of baseline and
steady-state samples were determined as described [24]. Glucose
disposal rate (GDR), in mg/kg/minute, was calculated as the rate
of tracer infusion (dpm/minute) divided by the plasma glucose-
specific activity (dpm/mg) corrected for body weight. Hepatic
glucose production (HGP), in mg/kg/min, was calculated as the
difference between the rates of glucose appearance and glucose
infusion.
Magnetic Resonance Spectroscopy (MRS) of Liver
Mice were anesthetized by continuous inhalation of 2%
isoflurane (Forene, Abbott, Ludwigshafen, Germany) in a
N2O:O2 (70:30 v:v) gas mixture. Liver lipid content was measured
by MRS using a Bruker BioSpecH 47/40 scanner (Bruker BioSpin,
Ettlingen, Germany) equipped with a BGA12 gradient coil system.
A volume coil was used for excitation and a surface coil for signal
reception. For anatomical orientation, a pilot scan containing
horizontal and axial images was acquired using a gradient-echo
pulse sequence with the following parameters: TR 135 ms; TE
3.5 ms; field of view 45645 mm
2; matrix 128
2 and slice thickness
1.75 mm. Based on the pilot scan, a voxel of interest
(36363m m
3) was placed in the left ventral part of the liver.
Liver lipids in the voxel of interest were measured using a point-
resolved spectroscopy (PRESS) sequence with the following
parameters: TR 1050 ms; TE 20 ms; number of averages 32
and digital resolution 1024 data points. Since the magnetic
resonance spectrum of a liver voxel contains signals from water
and lipids, liver lipid content was standardized and expressed as
the ratio (in %) between lipid signals and water signal. Data were
analyzed with commercially available LCModel software [25].
Table 2. Influence of linagliptin treatment on DPP-4 activity, serum GLP-1 concentrations, serum glucose during OGTT and liver TG
content.
DPP-4 inhibition
(% of vehicle treated) GLP-1 (pM)
Glucose AUC0–120 min (% reduction
compared with vehicle treated) Liver TG (mg/mg)
Study 1 (2 months HFD)
Vehicle NA 8.862.7 NA 31.362.5
Linagliptin 3 mg/kg/day 67*** 39.9623.6*** –16.5** 31.461.3
Linagliptin 30 mg/kg/day 79*** 46.265.9*** –14.5* 25.1361.4*
Chow fed 0.7 (NS) 12.963.3 (NS) –25.0*** 15.861.0***
Study 3 (3 months HFD)
Vehicle NA ND NA NP
Linagliptin 3 mg/kg/day 80*** 45.0610.0 –20.3** NP
Linagliptin 30 mg/kg/day 89*** 56.268.4 –26.4* NP
Chow fed 3 9.161.6 –25.5*** NP
Study 4 (4 months HFD)
Vehicle NA 2.360.4 NP 58.869.1
Linagliptin 3 mg/kg/day 78*** 26.862.5*** NP 41.262.7
Linagliptin 30 mg/kg/day 84*** 38.762.5*** NP 42.562.8
Chow fed 16 4.861.3 NP 21.862.8***
Values are given as mean 6 SEM. *P,0.05; **P,0.01; ***P,0.001 compared with vehicle-treated mice.
AUC, area under the curve; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; HFD, high-fat diet; NA, not applicable; ND, not detectable; NP, not performed;
NS, not significant; OGTT, oral glucose tolerance test; TG, triglycerides.
doi:10.1371/journal.pone.0038744.t002
Table 3. Effects of 4 weeks linagliptin treatment in C57BL/6N mice after 3 months of HFD (study 2; n=15 per experimental group)
on GLP-1 serum concentrations, food intake, body weight, fed glucose levels, HbA1c and liver triglyceride content.
GLP-1 (pM)
Food intake
(g/day) Body weight (g) Glucose (mM) HbA1c (%) Liver TG (mg/mg)
Vehicle ND 2.860.3 44.460.5 6.260.1 4.660.03 60.763.2
Linagliptin 3 mg/kg/day 18.464.0 3.160.2 44.360.7 5.860.8*** 4.360.03*** 47.962.4***
Linagliptin 30 mg/kg/day 26.463.7 3.160.4 44.761.6 5.760.07*** 4.360.03*** 39.162.4***
Chow fed 7.563.4 4.060.3 25.260.5 5.760.08*** 4.360.03*** 14.360.9***
Values are given as mean 6 SEM. ***P,0.001 compared with vehicle-treated DIO mice.
GLP-1, glucagon-like peptide-1; HbA1c, glycated hemoglobin; HFD, high-fat diet; ND, not detectable; TG, triglycerides.
doi:10.1371/journal.pone.0038744.t003
Linagliptin, Liver Fat and Insulin Sensitivity
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Histologic analyses of liver were performed after liver tissue
samples were fixed at room temperature in 4% formaldehyde and
embedded in paraffin. Five-micrometer sections were mounted on
glass slides, deparaffinized in xylol, and stained for hematoxylin
and eosin. Additional Oil Red O staining of the histologic slides
was used for the localization of lipids that exist as neutral lipids and
fatty acids. Quantification of Oil Red O staining was performed by
histologic scoring (n=9 animals per group).
SOCS3 immunohistochemisty was performed with Abcam
(ab16030) antibody in 1/200 dilution of pepsin pretreated slides.
Scoring was done by an experienced pathologist in a blinded
manner using a scoring scale from 0–4 (no, minimal, mild,
moderate, severe).
Measurement of mRNA Expression in Adipose Tissue and
Liver (Study 2)
Total RNA was isolated from epigonadal adipose tissue and
liver using TRIzol (Life Technologies, Grand Island, NY) and
1 mg RNA was reverse transcribed with standard reagents (Life
Technologies, Grand Island, NY). cDNA was prepared using the
Taqman reverse transcriptase kit (Applied Biosystems, Darmstadt,
Germany). From each reverse transcription polymerase chain
reaction (PCR) 2 ml were amplified in a 26 ml PCR reaction using
Brilliant SYBR Green QPCR Core Reagent Kit (Stratagene, La
Jolla, CA). The following primer pairs were used: sterol regulatory
element–binding protein-1c (SREBP1c), 59 ACA-
GAGCTTCCGGCCTGCTA 39 (sense) and 59 CCGAGCTG
TGGCCTCATGTA 39 (antisense); peroxisome proliferator–activated
receptor-a (PPARa), 59 TCAAGG TGTGGCCCAAG GTTA 39
(sense) and 59 CGAATGTTCTCAGAAGCCAGCT 39 (anti-
sense); stearoyl-CoA desaturase-1 (SCD-1), 59 GCCTGT ACGG-
GATCATACTGGTTC 39 (sense) and 59 CAGAGC GCTGGT
Figure 1. Effect of linagliptin on insulin sensitivity determined by euglycemic–hyperinsulinemic clamps in diet-induced obesity
(DIO) mice. C57BL/6 mice were fed a high-fat diet (HFD) or chow diet for 3 months followed by treatment with linagliptin (3 mg/kg/day or 30 mg/
kg/day) or placebo. Four weeks after treatment initiation, euglycemic–hyperinsulinemic clamps were performed to measure glucose disposal rate
(GDR) (A), dynamic of blood glucose concentrations (B), and GDR and hepatic glucose production (HGP) during the steady-state period of the
euglycemic–hyperinsulinemic clamp (C and D). (E–H) Tissue specific uptake of 2-deoxy-D-[1-
14C]glucose into gastrocnemius skeletal muscle (E), heart
muscle (F), perigonadal white adipose tissue (WAT) (G) and kidney (H). Blood glucose levels were determined every 10 minutes (B-Glucose Analyzer;
HemoCue AB, A ¨ngelholm, Sweden). Values are given as mean 6 SD. ***P,0.001 compared with DIO vehicle-treated group.
doi:10.1371/journal.pone.0038744.g001
Figure 2. Effect of linagliptin treatment on liver lipid content in
diet-induced obesity (DIO) mice. C57BL/6 mice were fed a high-fat
diet (HFD) for either 2 months and treated with linagliptin (3 mg/kg/
day or 30 mg/kg/day) or placebo for an additional 4 weeks (A), HFD for
3 months and treated with linagliptin (3 mg/kg/day or 30 mg/kg/day)
or placebo for an additional 3 weeks (B), or HFD for over 4 months and
treated with linagliptin (3 mg/kg/day or 30 mg/kg/day) or placebo for
an additional 4 weeks (C). Liver lipid content was determined using
magnetic resonance spectroscopy. Duration of HFD is displayed for the
individual graphs. Values are given as mean 6 SEM. *P,0.05; **P,0.01;
***P,0.001.
doi:10.1371/journal.pone.0038744.g002
Figure 3. Correlation of liver triglyceride content detected with
enzymatic assays and relative liver lipid content measured
with magnetic resonance spectroscopy.
doi:10.1371/journal.pone.0038744.g003
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(CPT1a), 59 AAGC CTTTGGGTG GTGGATATGTGA39
(sense) and 59 TGGAACTGGTGGCCAAT GAG39 (antisense);
acyl-CoA oxidase 1 (ACOX1), 59 CAGCGTTAC-
GAGGTGGCTGTTA39 (sense) and 59 TGCCCAA
GTGAAGGTCC AAAG 39 (antisense) and GLP-1 receptor,5 9
ATGGTGG CTATCCTGTAD TGCTTTTG 39 (sense) and 59
GCTGCTGGTGGGACACTTGA 39 (antisense). Expression of
mRNAs were quantified by using the second derivative maximum
method of the TaqMan software (Applied Biosystems, Darmstadt,
Germany), determining the crossing points of individual samples
by an algorithm which identifies the first turning point of the
fluorescence curve. Amplification of specific transcripts was
confirmed by melting curve profiles (cooling the sample to 68uC
and heating slowly to 95uC with measurement of fluorescence) at
the end of each PCR. Expression of hypoxanthine phosphoribosyl-
transferase 1, F4/80, protein tyrosine phosphatase 1B (PTP1B), fatty acid
synthase (FAS), suppressor of cytokine signaling 2 (SOCS2) and suppressor of
cytokine signaling 3 (SOCS3) was measured using TaqMan Gene
Expression Assays (Applied Biosystems, Darmstadt, Germany).
Figure 4. Evaluation of effect of linagliptin on hepatic steatosis. Oil Red O staining of liver specimens from diet-induced obesity (DIO) mice
treated with vehicle (A), DIO mice treated with linagliptin 3 mg/kg/day (B), DIO mice treated with linagliptin 30 mg/kg/day (C) and chow-fed mice (D).
Quantification of Oil Red O staining was performed by histologic scoring (n=9 animals per group) (E). Data are shown as mean 6 SEM. **P,0.01;
***P,0.001.
doi:10.1371/journal.pone.0038744.g004
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Blood glucose and glycated hemoglobin (HbA1c) values were
determined from 5-ml whole venous blood samples using an
automated glucose monitor (HITADO Blutglukose Analyzer
Super GL, Mu ¨nster, Germany). Fasting glucose levels and
capillary blood glucose measurements were determined from
1 ml of tail vein samples using a Freestyle Mini Analyzer (Abbott,
Figure 5. Effects of linagliptin on macrophage infiltration into adipose tissue and on liver mRNA expression of key molecules in
liver metabolism and inflammation. (A) mRNA expression of F4/80 and (B) number of F4/80 positive cells in epigonadal adipose tissue of C57BL/
6 mice which were fed a high-fat diet (HFD) or chow diet for 3 months followed by treatment with linagliptin (3 mg/kg/day or 30 mg/kg/day) or
placebo for 4 weeks. (C) mRNA expression of protein tyrosine phosphatase 1B (PTP1B), suppressor of cytokine signaling 2 (SOCS2), suppressor of cytokine
signaling 3 (SOCS3), sterol regulatory element–binding protein-1c (SREBP1c), peroxisome proliferator–activated receptor-a (PPARa), stearoyl-CoA
desaturase-1 (SCD-1), fatty acid synthase (FAS), carnitine palmitoyl transferase 1a (CPT1a), acyl-CoA oxidase 1 (ACOX1), and GLP-1 receptor in the liver of
C57BL/6 mice which were fed a high-fat diet (HFD) or chow diet for 3 months followed by treatment with linagliptin (3 mg/kg/day or 30 mg/kg/day)
or placebo for 4 weeks. mRNA expression was calculated relative to the mRNA expression of hypoxanthine phosphoribosyltransferase 1 (HPRT-1). Data
are shown as mean 6 SEM. *P,0.05 vs. vehicle.
doi:10.1371/journal.pone.0038744.g005
Linagliptin, Liver Fat and Insulin Sensitivity
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reported [15].
Statistical Analyses
Data are means 6 standard deviation unless stated otherwise.
Before statistical analysis, non-normally distributed parameters
were logarithmically transformed to approximate a normal
distribution. The following statistical tests were performed using
SPSS version 12.0 (Chicago, IL): unpaired Student’s t-test;
ANOVA and Pearson’s simple correlation. Linear relationships
were assessed by least square regression analysis. P values of ,0.05
were considered statistically significant.
Results
Effects of Long-term Linagliptin Treatment on Serum
DPP-4 Activity and GLP-1 Levels
DPP-4 activity was significantly reduced and GLP-1 levels were
significantly increased in all the studies at both linagliptin doses,
compared with treatment with vehicle alone (P,0.001 for all
comparisons; Table 2).
Effects of Linagliptin on Glucose Metabolism
Treatment of DIO mice for 4 weeks with either dose of
linagliptin (study 2) significantly lowered fed blood glucose
concentrations and HbA1c (both P,0.001) compared with
treatment with vehicle (Table 3). In studies 1 and 3, blood
glucose levels during oral glucose tolerance tests measured as
area under the curve were significantly suppressed compared
with vehicle: –16.5% and –20.3% with linagliptin 3 mg/kg/day
(P,0.01, both studies); and –14.5% and –26.4% with linagliptin
30 mg/kg/day (P,0.05, both studies; Table 2).
Effect of Linagliptin on Insulin Sensitivity
Significant dose-dependent increases were seen in GDR during
the steady-state period of the euglycemic–hyperinsulinemic clamp
in the linagliptin-treated groups (27.3 mg/kg/minute and
32.2 mg/kg/minute in the 3 mg/kg/day and 30 mg/kg/day
groups, respectively), compared with vehicle-treated DIO mice
(20.9 mg/kg/minute; P,0.001 for both comparisons; Figure 1A–
C). Chow-fed mice displayed still higher GDRs (46.2 mg/kg/
minute) compared with vehicle-treated DIO mice (P,0.001;
Figure 1C). Insulin-mediated suppression of HGP was significantly
higher in both linagliptin-treated groups compared with vehicle-
treated DIO mice during the steady-state period of the clamp
(both P,0.001; Figure 1D). A notable finding was that the
suppression of HGP in DIO mice treated with linagliptin 30 mg/
kg/day was not statistically different from that of chow-fed mice
(Figure 1D). Linagliptin treatment did not affect food intake or
body weight in DIO mice (Table 3). There was a dose-dependent,
but non-significant trend for higher 2-deoxy-D-[1-
14C]glucose
concentrations in the skeletal muscle, heart and kidneys of DIO
mice treated with linagliptin compared with vehicle, whereas no
such trend was observed in adipose tissue (Figure 1E–H).
Effect of Linagliptin on Liver Lipid Content
Liver fat was detected by MRS (studies 1, 3 and 4; Figure 2) and
with biochemical methods (studies 1, 3 and 4; Table 2 and study 2;
Table 3). Additionally, liver fat content was evaluated by histologic
examination of Oil Red O-stained specimens from study 4.
Treatment of DIO mice with linagliptin reduced liver lipid content
at 2, 3 and 4 months, with linagliptin 30 mg/kg/day significantly
reducing liver lipid content (P,0.01) after 2 and 3 months of high-
fat diet feeding (Figure 2). As expected, the chow-fed group always
had the lowest liver lipid content independent of the study protocol
(Figure 2). There was a highly significant correlation (r
2=0.56;
P,0.001) between data obtained by MRS and biochemical
triglyceride detection (Figure 3). Linagliptin-mediated reductions
in liver triglyceride content were also significantly correlated with
improvement in blood glucose (r
2=0.2, P,0.01) and HbA1c
(r
2=0.18; P,0.01). Oil Red O-stained specimens from study 4
provided visual evidence of linagliptin-mediated liver fat reduction
(Figure 4A–D), while quantification by histologic scoring revealed
significant decreases in liver fat at both doses of linagliptin (3 mg/
kg/day, P,0.001; and 30 mg/kg/day, P,0.01) compared with
vehicle treatment (Fig. 4E).
Effect of Linagliptin on Macrophage Infiltration into
Adipose Tissue
Linagliptin treatment had no effect on mean adipocyte size in
the epigonadal fat depot. In mice treated with 30 mg/kg/day
linagliptin (as well as in chow-fed controls), a significantly lower
(P,0.05) expression of the macrophage marker F4/80 was found
compared with vehicle treatment (Figure 5A). These differences
reflect a lower number of macrophages in the 30 mg/kg/day
linagliptin treatment and chow-fed groups (Figure 5B).
Effect of Linagliptin on mRNA Expression of Key
Molecules in Liver Metabolism and Inflammation
Linagliptin treatment had a significant effect on the mRNA
expression of several genes involved in the inflammatory response,
fatty acid synthesis and oxidation. In parallel with reduced liver fat
content, significantly decreased expression (P,0.05) of PTP1B,
SOCS3, SREBP1c, SCD1 and FAS with 30 mg/kg/day linagliptin
treatment (Figure 5C) was found. There was no significant effect of
the 3 mg/kg/day linagliptin dose on the expression of these genes.
By contrast, linagliptin treatment had no effect on SOCS2,
PPARa, CPT1a, ACOX1 or GLP-1 receptor mRNA expression
(Figure 5C).
Figure 6. Effects of linagliptin on liver Suppressor of cytokine
signaling 3 (SOCS3) protein expression. SOCS3 protein staining of
liver specimens from diet-induced obesity (DIO) mice treated with
vehicle, linagliptin 3 mg/kg/day (B), linagliptin 30 mg/kg/day (C) and
chow-fed mice (D). Quantification of staining was performed by
histologic scoring (n=9 animals per group). Data are shown as mean
6 SEM. *P,0.05.
doi:10.1371/journal.pone.0038744.g006
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protein in the liver. The immunohistochemical staining for
SOCS3 revealed a minimal to moderate, cytoplasmic staining of
liver cells in a diffuse pattern. It was most severe in the vehicle
group and showed a progessive decrease in linagliptin groups of
3 mg/kg and 30 mg/kg as well as chow treated animals (Figure 6).
Following quantification the latter two groups were also signifi-
cantly reduced. These data were in accordance to the results
obtained for mRNA levels of SOCS3 (Figure 5C).
Discussion
Linagliptin, a DPP-4 inhibitor, shows highly selective, potent,
dose-dependent inhibition of the enzyme with .80% inhibition
maintained throughout the 24-hour dosing interval [26]. In
addition, linagliptin has a favorable pharmacokinetic profile as it is
eliminated predominantly in the feces [4,19]. Linagliptin is more
effective than placebo in improving glycemic control both as
monotherapy [27,28] and in combination therapy with other oral
agents, e.g. with pioglitazone [29]. Recently, it has been suggested
that linagliptin may improve insulin sensitivity [29]. Furthermore,
in a recent clinical pilot study, the DPP-4 inhibitor vildagliptin
improved peripheral glucose utilization [20]. In the present study,
we investigated the effects of 3 or 4 weeks of linagliptin treatment
on DIO mice with respect to glucose metabolism and hepatic
steatosis.
The key finding of our study is that linagliptin caused a dose-
dependent improvement in insulin sensitivity in DIO mice as
evaluated by GDR and insulin-mediated suppression of HGP. In
addition, linagliptin reversed liver triglyceride content and
improved hepatic steatosis in a dose-dependent manner, which
correlated with improvements in blood glucose concentration and
HbA1c. These data were consistently obtained, irrespective of the
duration of high-fat diet preconditioning or linagliptin treatment.
In all studies, linagliptin treatment significantly reduced DPP-4
activity and increased serum GLP-1 levels.
The improvement of insulin sensitivity in response to linagliptin
treatment was a somewhat unanticipated finding. The main
mechanisms by which DPP-4 inhibition lowers glucose levels are
by improving glucose-dependent insulin secretion and reducing
postprandial glucagon secretion [1–3]. A direct effect of either
GLP-1 or GIP on glucose uptake cannot be excluded. In either
case, it is possible that improved glycemia may reduce glucose
toxicity-associated insulin resistance and thereby increase insulin
sensitivity. However, while linagliptin treatment significantly
reduced HbA1c in DIO mice, it was already low in vehicle-
treated mice at 4.6%. Previously, the effects of glucose toxicity on
insulin resistance have been previously reported with much larger
reductions in glucose levels [30].
Another possible mechanism underlying linagliptin-induced
improvements in glucose disposal is reduced lipotoxicity. Liver
fat content correlates with the metabolic syndrome independent of
obesity and may increase the risk for T2DM and atherosclerosis
[30,31]. Fat can accumulate in the liver through excess dietary fat
(DIO mouse model), increased delivery of free fatty acids to the
liver, inadequate fatty acid oxidation and increased de novo
lipogenesis [31]. Stored triglycerides in muscle and liver may be
reduced through reduction in fasting free fatty acid flux. However,
the effects of linagliptin on free fatty acid flux or lipolysis were not
tested and will require further investigation. Moderately hypoca-
loric, reduced-fat diets can decrease hepatic lipid content by
approximately 40–80% [32]. Treatment with thiazolidinediones
reduces hepatic steatosis by 30–50% by modulating insulin
sensitivity and endocrine function of adipose tissue in T2DM
[33]. However, metformin, an antihyperglycemic drug, improves
hepatic insulin action without affecting liver lipid content [32]. In
our study, there was a significant decrease in liver lipid content in
linagliptin-treated DIO mice; liver fat content was reduced by up
to 30% and insulin sensitivity was improved by up to 35%. Indeed,
improved hepatic steatosis is the strongest predictor of improved
glucose homeostasis. These data support the hypothesis that
decreased lipotoxicity in response to linagliptin treatment may
result in improved insulin sensitivity. Further studies comparing
the effects of linagliptin with other glucose-lowering drugs on
improved insulin sensitivity and reduced liver fat content may help
to find the mechanisms underlying these beneficial effects of
linagliptin treatment.
Shirikawa and coworkers (2011) recently investigated the effects
of sitagliptin on adipose tissue inflammation and liver steatosis
[23]. In b-cell-specific glucokinase haploinsufficient diabetic mice
challenged with diets containing a combination of sucrose with
either oleic or linoleic acid, they found that DPP-4 inhibition
significantly prevented adipose tissue infiltration by macrophages,
decreased the expression of plasminogen activator inhibitor-1 and
prevented fatty liver [23]. In the liver, DPP-4 inhibition also
decreased the expression of SREBP-1c, SCD-1 and FAS, and
increased the expression of PPARa. We therefore tested the
hypothesis that linagliptin may have similar effects on adipose
tissue biology and liver mRNA expression in our study. In
accordance with Shirikawa et al [23], we found a significantly
reduced number of macrophages infiltrating adipose tissue with
30 mg/kg/day linagliptin treatment, whereas the 3 mg/kg/d dose
was not sufficient to reduce adipose tissue inflammation.
Moreover, we found significantly reduced liver mRNA expression
of PTP1B and SOCS3 in the 30 mg/kg/day linagliptin treatment
group. PTP1B has been implicated in the development of
inflammation and insulin resistance associated with obesity during
aging [34]. SOCS3 is increased in inflammation and is thought to
contribute to the pathogenesis of insulin resistance by inhibiting
insulin signaling [35]. Collectively, the reduction of macrophage
numbers in adipose tissue, as well as the decreased liver expression
of PTP1B and SOCS3 (for the latter also protein was reduced), may
reflect the improved inflammatory status of these key insulin target
organs with linagliptin treatment. These data suggest that
decreasing inflammation at the organ level in mice treated with
linagliptin 30 mg/kg/day may contribute to improved whole body
insulin sensitivity. In addition, linagliptin (30 mg/kg/day dose
only) significantly reduced SREBP1c, SCD1 and FAS expression.
These data are in accordance with the effects of sitagliptin
treatment on liver gene expression [23]. However, with the study
design used we cannot distinguish whether reduced SREBP1c,
SCD1 and FAS expression cause, or are merely markers of, a
reduction in liver fat content. Further studies are required to find
the potential direct effects of DPP-4 inhibition on these genes
associated with hepatic steatosis. In our model system, we did not
find significant effects of linagliptin on the expression of genes
involved in fatty acid oxidation (CPT1a and ACOX1) and the GLP-
1 receptor suggesting that alterations of these pathways are not
primarily responsible for improved insulin sensitivity and reduced
liver fat content in linagliptin-treated DIO mice.
In conclusion, although the current study design cannot
distinguish whether significantly improved insulin sensitivity in
response to long-term treatment with linagliptin is a direct or
secondary effect, the data suggest that it may be the result of
significantly reduced liver fat content in diet-induced hepatic
steatosis and insulin resistance animal model. These results may
further qualify the use of linagliptin in pathophysiological
conditions of fatty liver diseases.
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